SAB Biotherapeutics, Inc. — Investor Relations & Filings
SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer) | 2026-05-04 | English | |
| 8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer) | 2026-04-22 | English | |
| S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer) | 2026-03-31 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 4 Filing | 2026-02-05 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41052858 | 8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer) | 2026-05-04 | English | ||
| 35241988 | 8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer) | 2026-04-22 | English | ||
| 33122956 | S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer) | 2026-03-31 | English | ||
| 31978875 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31978836 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31978829 | 4 Filing | 2026-02-05 | English | ||
| 31978797 | 4 Filing | 2026-02-05 | English | ||
| 31978757 | 4 Filing | 2026-02-05 | English | ||
| 31978667 | 4 Filing | 2026-02-05 | English | ||
| 31978629 | 4 Filing | 2026-02-05 | English | ||
| 13343909 | Major Shareholding Notification 2026 | 2026-01-22 | English | ||
| 13343908 | 8-K | 2026-01-12 | English | ||
| 13343912 | Regulatory Filings 2026 | 2026-01-08 | English | ||
| 13343910 | 4 | 2026-01-07 | English | ||
| 13343911 | 4 | 2026-01-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
SAB Biotherapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34961/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34961 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34961 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34961 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34961}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SAB Biotherapeutics, Inc. (id: 34961)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.